Equities Analysts Set Expectations for Alkermes Q4 Earnings

Alkermes plc (NASDAQ:ALKS) – Zacks Research upped their Q4 2025 EPS estimates for Alkermes in a research report issued on Thursday, October 23rd. Zacks Research analyst Team now anticipates that the company will post earnings of $0.38 per share for the quarter, up from their prior estimate of $0.37. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Alkermes’ current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes’ Q1 2026 earnings at $0.45 EPS, Q2 2026 earnings at $0.49 EPS, Q3 2026 earnings at $0.37 EPS, Q4 2026 earnings at $0.45 EPS, FY2026 earnings at $1.77 EPS, Q1 2027 earnings at $0.34 EPS and Q2 2027 earnings at $0.46 EPS.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.10. The firm had revenue of $390.66 million during the quarter, compared to analysts’ expectations of $343.20 million. Alkermes had a net margin of 23.15% and a return on equity of 24.86%. The business’s revenue for the quarter was down 2.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.16 earnings per share.

ALKS has been the subject of several other research reports. Wells Fargo & Company upgraded shares of Alkermes to a “strong-buy” rating in a report on Wednesday, September 3rd. The Goldman Sachs Group assumed coverage on shares of Alkermes in a report on Tuesday, July 15th. They issued a “buy” rating and a $43.00 price target for the company. Royal Bank Of Canada upped their price target on shares of Alkermes from $45.00 to $47.00 and gave the company an “outperform” rating in a report on Wednesday, October 22nd. HC Wainwright reiterated a “neutral” rating on shares of Alkermes in a report on Wednesday, October 22nd. Finally, Piper Sandler reiterated an “overweight” rating and issued a $45.00 price target (up previously from $38.00) on shares of Alkermes in a report on Thursday. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $43.25.

Alkermes Stock Down 0.3%

Alkermes stock opened at $29.72 on Monday. The stock has a market capitalization of $4.91 billion, a PE ratio of 14.29, a price-to-earnings-growth ratio of 1.61 and a beta of 0.54. Alkermes has a twelve month low of $25.17 and a twelve month high of $36.45. The company has a 50 day moving average of $29.44 and a 200-day moving average of $29.16.

Insider Activity at Alkermes

In other news, EVP Craig C. Hopkinson sold 9,000 shares of the business’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $31.53, for a total value of $283,770.00. Following the sale, the executive vice president owned 73,740 shares of the company’s stock, valued at $2,325,022.20. The trade was a 10.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Alkermes

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Intech Investment Management LLC raised its position in Alkermes by 25.6% during the first quarter. Intech Investment Management LLC now owns 85,564 shares of the company’s stock worth $2,825,000 after acquiring an additional 17,413 shares in the last quarter. Baird Financial Group Inc. bought a new stake in Alkermes during the first quarter worth $587,000. Victory Capital Management Inc. raised its position in Alkermes by 30.9% during the first quarter. Victory Capital Management Inc. now owns 120,997 shares of the company’s stock worth $3,995,000 after acquiring an additional 28,596 shares in the last quarter. GAMMA Investing LLC raised its position in Alkermes by 31.9% during the first quarter. GAMMA Investing LLC now owns 5,396 shares of the company’s stock worth $178,000 after acquiring an additional 1,305 shares in the last quarter. Finally, Acadian Asset Management LLC raised its position in Alkermes by 2,422.0% during the first quarter. Acadian Asset Management LLC now owns 881,827 shares of the company’s stock worth $29,100,000 after acquiring an additional 846,861 shares in the last quarter. 95.21% of the stock is owned by institutional investors.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.